Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Mark DeVito as its Senior Director of Equity Trading.

Roberts & Ryan, Inc.

Mr. DeVito joins Roberts & Ryan as a seasoned business veteran, whose 35-year career has included leadership roles in investment banking, corporate finance, capital market transactions, alternative investments, and corporate boards. Prior to joining Roberts & Ryan, Mr. DeVito was Managing Director of the Global Investment Banking Group at Bank of America Securities, where he developed key client relationships and originated investment banking transactions. Before Bank of America Securities, Mr. DeVito was Managing Partner at JCS Partners LLC. Prior to that, he was Managing Director of Global Energy and Power Investment Banking at Merrill Lynch. Additionally, while at Merrill Lynch, he was the Global Head of their Alternative Investments Group and Managing Director of their Debt Capital Markets Group. Prior to that, he was Senior Vice President of Investment Banking and Capital Markets at Lehman Brothers and Assistant Vice President at Shearson Lehman Hutton. Mr. DeVito served as a member of the Board of Directors of Nextremity Solutions, the Board of Trustees of Rumson Country Day School and the Executive Board of Family and Children’s Services. When asked to share his thoughts on Roberts & Ryan's latest appointment, Chief Executive Officer Ed D'Alessandro remarked, “I am very excited to welcome Mark to our team. His extensive experience and distinguished investment banking career will be a tremendous asset to Roberts & Ryan. Mark is committed to our social mission of supporting Veterans and their families, and his investment banking experience will be instrumental in helping us grow. We are truly fortunate to have someone of Mark’s caliber join our team to help us get to the next level.” Mr. DeVito is a graduate of Fordham University’s Gabelli School of Business, where he received an MBA in Finance, and a graduate of Seton Hall University, where he received a BA in Finance. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, primarily focusing on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 08, 2024 09:00 AM Eastern Standard Time

Image

Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech’s Investigational Alzheimer’s Treatment Shows Positive Trial Results

Benzinga

By Meg Flippin, Benzinga Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to slow the effects of life-threatening and chronic aging-related conditions using cellular therapies, is making inroads with Lomecel-B™, its investigational treatment for hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and aging-related frailty. On October 5th, the Miami-based biotech announced that Lomecel-B™ met its primary safety endpoint and showed a lack of deterioration in cognitive or atrophy signals in approximately 50 patients aged 60 to 85 years old with mild Alzheimer’s disease, marking a major milestone for the company. The successful trial paves the way for more clinical studies of this potentially game-changing treatment. “We believe these results provide important validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of Alzheimer’s disease and provide a robust foundation for additional clinical trials in this and other indications,” Wa’el Hashad, CEO of Longeveron, said announcing the trial results. In late December, the company released additional new clinical and biomarker results from the trial that reinforced the earlier top-line findings. Additional analysis of cognitive function and daily living data showed favorable results with Lomecel-B™ over placebo. The drug was shown to slow and in some cases improve certain measurements of cognitive function (MoCA, MMSE). Funding Development In addition to reporting promising results for Lomecel-B™, in October 2023, Longeveron secured $4 million in gross proceeds before expenses from a round of equity financing. In late December, Longeveron closed a previously announced registered direct offering of 1.35 million shares priced at $1.62 per share, raising an additional $2.36 million in gross proceeds. Longeveron plans to use the net proceeds to fund the ongoing clinical and regulatory development of Lomecel-B™ and for capital expenditures, working capital, and general corporate purposes. The company reported that as of the end of the third quarter, it has enough existing cash and short-term investments to cover expenses and capital requirements into the first quarter of 2024. Investor Aspirations And Stock Trend Some investors are hopeful that Lomecel-B™ could possibly play a role in the future in treating Alzheimer’s disease, which affects about 6.7 million people 65 and older in the U.S. In 2023 alone, Alzheimer’s and other dementias will cost the U.S. $345 billion, according to the Alzheimer’s Association. By 2050, total payments for healthcare, long-term care and hospice for those with dementia are projected to reach nearly $1 trillion. Lomecel-B™ appears to target inflammation, and it is believed that inflammation plays a role in the onset and progression of Alzheimer’s disease. Researchers made this discovery after several studies showed that people who took anti-inflammatory drugs like Enbrel and Humira were as much as 50% less likely to develop Alzheimer's disease later in life. These discoveries have in part helped to spur a new class of investigational drugs that aim to treat and cure Alzheimer’s disease by targeting inflammation. Lomecel-B™ is made from medical signaling cells (MSCs) derived from the bone marrow of healthy adult donors. It is believed that these cells travel to sites of damage or inflammation in the body and promote cellular regeneration and repair. More Potential Catalysts On The Horizon? Lomecel-B™ as a potential treatment for Alzheimer’s isn’t the only possible catalyst on the horizon for Longeveron, and investors may want to watch for more to come. The therapeutic treatment is also in stage 2 trials to treat Hypoplastic Left Heart Syndrome (HLHS) and Aging-related frailty. HLHS is a rare pediatric congenital heart defect that affects about 1,000 babies in the U.S. annually. The left side of the heart fails to develop in patients with HLHS – leading to short-term mortality, delayed development and long-term organ failure. Lomecel-B™ is administered directly into the cardiac tissue of the right ventricle for HLHS patients. The goal is to improve cardiac function through the regenerative, pro-vascular and anti-inflammatory effects of MSCs. Results from a phase 1 ELPIS 1 trial showed 100% survival in Lomecel-B™-treated children at up to five years of age. Historically, children with HLHS have about 20% mortality by five years. The results were encouraging enough for Lomecel-B™ to be given the Rare Pediatric Disease Designation (RPD), Orphan Drug Designation (ODD) and Fast Track Designation from the FDA. A phase 2 trial in HLHS of 38 patients is currently underway. In August, the trial surpassed the 50% enrollment threshold. The company is also in a phase 2 trial of Lomecel-B™ to treat aging-related frailty, which is characterized by mobility disability, weakness, fatigue, weight loss, slowness and low activity. Its current phase 2 trial will include 45 patients in Japan, where nearly a third of the population is over 65. “With our Phase 2 ELPIS II trial in HLHS moving toward anticipated completion in 2024, and our Phase 2 program in Aging-related frailty progressing in Japan as well, we look forward to meaningful milestones in the near term and to fully realizing the therapeutic potential of Lomecel-B™,” said Hashad. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 08, 2024 08:45 AM Eastern Standard Time

Redx Pharma lands biggest deal to date with sale of KRAS inhibitor programme to Jazz Pharma

Redx Pharma PLC

Redx Pharma PLC CEO Lisa Anson joins Proactive's Stephen Gunnion with details of a landmark partnership with Jazz Pharmaceuticals, marking its largest deal to date. Anson explained the agreement involves the sale of Redx's KRAS programme, a key preclinical discovery initiative targeting genetic mutations driving various cancers. The $10 million upfront deal could potentially be followed by a further $870 million in milestone payments, signifying a major step forward for Redx in cancer research. The KRAS programme focuses on combating hard-to-treat cancers, such as colorectal, lung, and pancreatic cancers, by targeting specific genetic mutations. The partnership aligns with RedX's strategy to balance in-house program development with collaborations that accelerate patient access to new treatments. Anson emphasised the significance of partnerships in advancing their clinical-stage biotech research and development efforts. The deal not only provides immediate financing but also ensures Redx maintains a vested interest in the program's success through potential milestones and mid-single digit royalties on future sales. Looking ahead, RedX anticipates a busy 2024 with several key milestones, including advancing its fibrosis and oncology programs, further demonstrating its commitment to addressing unmet medical needs. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:47 AM Eastern Standard Time

Video

Futura Medical marks pivotal year with first meaningful revenue from Eroxon sales

Futura Medical PLC

Futura Medical PLC CEO James Barder tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company as it rolled out its innovative sexual health product, Eroxon, designed to treat erectile dysfunction. The over-the-counter availability of Eroxon distinguishes it as a groundbreaking product globally, facilitating easier access for consumers without a prescription. Barder noted the company reported significant achievements in 2023, including revenue of £3.1 million and a strategic expansion into the US market, bolstered by FDA approval and a partnership with leading OTC distributor Halen. This expansion is underscored by successful launches in the UK and Belgium, capturing around a 20% market share. Barder highlighted Futura's virtual organizational model and risk-mitigated marketing strategy through partnerships focusing on advertising and promotional spend. Looking ahead, Futura anticipates further global expansion with more than ten country launches expected by April, surpassing initial forecasts. Additionally, the company's vigilant stance against counterfeit products underscores its commitment to safeguarding brand integrity and consumer trust. With new broker and investor relations appointments, Futura aims to enhance shareholder value and visibility. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:31 AM Eastern Standard Time

Video

Poolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assets

Poolbeg Pharma PLC

Poolbeg Pharma PLC's newly appointed Vice President of Clinical Operations Laura Maher joined Proactive's Stephen Gunnion to discuss her role at the company. Maher detailed her responsibilities at Poolbeg, emphasising her leadership in developing and managing clinical programs. She highlighted the importance of collaborations, both internally and with external service providers, to ensure the acquisition of quality data. Maher's significant achievements at Amryt include her pivotal role in the development and approval of Filsuvez, a treatment for Epidermolysis Bullosa (EB). She oversaw the largest-ever EB trial, leading to EMA approval in June 2022, marking it as the world’s first approved treatment for EB. Despite initial FDA rejection, her perseverance led to eventual FDA approval in December 2023. Her extensive background in clinical research and operations, beginning with a research master's degree and experience in various roles across academia and small pharmaceutical companies, informs her approach at Poolbeg. Maher expressed her enthusiasm for working in a dynamic environment like Poolbeg, particularly excited about their cancer immunotherapy and cytokine release syndrome projects. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 08, 2024 06:27 AM Eastern Standard Time

Video

Startup Reduces Sugar In Natural Beverages Without Spoiling The Taste; Juice, Dairy Industries Could Be Ripe For BlueTree Technologies

OurCrowd

by Jeremy Ruden More than half of the global population – 51%, or over 4 billion people – will be obese by 2035, according to a 2023 report from the World Obesity Atlas. One of the major causes of obesity is sugar. While candy and carbonated drinks might be on many people’s radars as a primary source of sugar, natural beverages such as orange juice are also packed with it. With these health concerns in mind, scientists at startup BlueTree Technologies created proprietary technology that removes up to 50 percent of the sugar from juice and other natural beverages. BlueTree’s innovative method selectively removes a specific sugar molecule, preserving the beverages’ natural taste and health benefits. The company is now raising a funding round through OurCrowd, the global equity investment platform. “Our technology targets the disaccharides in the juice without harming the other ingredients,” says Yossi Sefi, BlueTree’s Chief Technical Officer. “It is capable of locating the exact kind of sugar in orange juice, for example, and removing it without harming the pulp, the vitamin C, the amino acids, or any other important ingredients.” In tests, half of those surveyed reported they preferred the flavor of orange juice with less sugar – while noticing no difference in the aroma and texture from the original. Successful Pilot The company, which was nurtured at the Fresh Start FoodTech incubator in northern Israel established by OurCrowd with Tnuva, Tempo and Finistere Ventures, has successfully adapted its technology for commercial applications. “We developed a turnkey platform that can be easily integrated into any manufacturing line,” says Michael Gordon, BlueTree’s CEO, who was formerly a senior director at Coca-Cola before joining the company. Gordon oversaw BlueTree’s first major deployment at a plant belonging to Priniv, one of the top three natural juice manufacturers in Israel. “It took us no more than two months to fully integrate our system and we did it without interfering with the plant’s overall operations,” Gordon says. BlueTree built all the equipment and the machinery for the Priniv installation in-house. The facility can now produce some 10,000 liters of orange juice daily, with up to 50% less sugar. BlueTree is poised for full-scale commercial production, with patents secured in the EU and Brazil, while awaiting approval from the Israeli Ministry of Health and the U.S. Food and Drug Administration. International beverage manufacturers and distributors, working to produce healthier products and avoid warning labels or progressive taxes on sugary drinks, are also showing a great deal of interest in BlueTree’s platform. The company signed an agreement with a leading international manufacturer, which it hopes will result in revenues of at least $6 million a year. It is also in advanced negotiations with other global producers in Italy and Spain and major juice manufacturers in Brazil and Thailand. One Platform The dairy industry is another target for BlueTree’s technology. Working together with a major local food manufacturer, the company produced a prototype that reduced the sugar in skimmed milk by some 75%. Commercialization plans are underway. The company also began an R&D project for beer with an international beverage manufacturer. The agreement forecasts the production of more than 200 million liters of reduced-sugar beer a year. “We can make the world better by reducing the sugar from all of nature’s liquids for all consumers,” Gordon says. “Our versatile tech could help curb the obesity crisis by cutting two teaspoons of sugar from children’s daily diet.” For more information about investing in BlueTree via OurCrowd, click HERE. Featured photo courtesy of BlueTree Technologies. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

February 07, 2024 08:15 AM Eastern Standard Time

Image

News Release

Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India

Kadimastem

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the Indian Patent and Trademark Office for its cell therapy technology. The cell sorting patent will be protected until November 2036 for the company's innovative cell selection and enrichment technology. This patent covers the production of IsletRx, the company's product for the treatment and potential cure for diabetes. The company's technology is unique with its ability to select and enrich only the highest functioning and purest islet cells from the population of differentiated islet-like cells which enables the maximum therapeutic effect. According to the Indian Ministry of Home Affairs, CNN and the pharmaletter India is a fastest growing economy of the global G20 with massive investments in web infrastructure and growing pharma and biotech sectors. As such biotech companies are increasingly securing their IP in India to ensure maximal potential revenues in the Indian subcontinent[1]. The approval of this patent in India is particularly important, especially in light of our collaboration project with iTolerance, a US company in the diabetes field and funded by the BIRD Foundation. The project combines Kadimastem’s and iTolerance’ s technologies to develop and commercialize a breakthrough regenerative technology to cure diabetes without the need for life-threatening chronic immuno-suppression. The project received a US $1Million grant from the BIRD Foundation for this project. Out of a total budget of US $2 Million In addition, according to statista in 2021, India was ranked second in the world with about 74.2 million diabetic adults in the 20 to 79 years old age group. The number of diabetic individuals was projected to increase to over 124 million in 2045[2]. In financial year 2021, the market size of diabetes and pre-diabetes care market in India was valued at about 17 billion U.S. dollars. It is forecasted to reach about 34 billion dollars in 2026 and 59 billion dollars in 2031[3]. Asaf Shiloni, company CEO: “Kadimastem highly believes that the company’s treatment can improve the quality of lives for hundreds of thousands of those dealing with the daily struggles of insulin dependent diabetes (IDD) by presenting a potential cure for IDD with our unique patented solution with IsletRx cells.” In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article [4] in Frontiers in Endocrinology. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About IsletRx The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes. Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Social Media: LinkedIn, Twitter, Facebook [1] Press Information Bureau (pib.gov.in); Indian economy regains its swagger as China stumbles | CNN Business; India's booming bioeconomy poised for growth (thepharmaletter.com) [2] https://www.statista.com/statistics/1360381/india-number-of-adults-with-diabetes/ [3] https://www.statista.com/statistics/1359258/india-diabetes-and-pre-diabetes-care-market-size/ [4] https://www.frontiersin.org / articles/10.3389/fendo.2021.635405/full Contact Details Kadimastem Asaf Shiloni CEO s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

February 07, 2024 07:23 AM Eastern Standard Time

Primer Selected for the 2024 GSV Cup 50

Spark Metro PR

Primer has been named to the 2024 GSV Cup 50 out of 1,000 nominations of pre-seed and seed-stage companies. The GSV Cup, presented by Google Cloud and GSV Ventures, and supported by HolonIQ, recognizes the world's most innovative digital learning and workforce skills startups. The GSV Cup 50 will be featured at the 15th Annual ASU+GSV Summit, the preeminent global gathering for “Pre-K to Gray” education leaders, in San Diego, CA. The GSV Cup 50 highlights the most promising startups that support learners across the Pre-K to Gray spectrum, distributed across early childhood education, K-12, higher education, workforce learning, and adult consumer learning. All nominees were evaluated against GSV’s “Five P’s” framework: People, Product, Potential, Predictability, and Purpose. "Being chosen for the GSV Cup 50 is a great honor, highlighting our alignment with GSV's values and our commitment to innovation in digital learning,” said Mark Naufel, Founder of Primer. “Being part of this elite group starts a new chapter for Primer, as we continue to revolutionize the idea of a lifelong adaptive learning experience powered by an AI personal companion." “This year’s GSV Cup was both incredibly competitive and incredibly inspiring,” said Deborah Quazzo, Managing Partner of GSV Ventures and Co-founder of the ASU+GSV Summit. “The GSV Cup 50 are undoubtedly the stars of tomorrow. With almost 80% of the companies focused on leveraging AI, they’ve got both eyes on the future of education – not just what we can see now, but what we can build beyond view. We’re so excited to see the transformative effects of these companies over the next five, ten, even fifteen years.” The 2024 GSV Cup 50 companies are poised to make a global impact, with 34% headquartered outside of the United States and representation from 15 unique countries. This year’s GSV Cup 50 also represent a variety of diverse perspectives and experiences, with 66% of the companies led by female or BIPOC founder(s). The GSV Cup 50 join a prestigious group of past Cup startups, including Ello, Ethena, LingoAce, Prenda, Stride, TransfrVR, and TeachFX. See Primer and all of the companies selected to the GSV Cup 50 at https://www.asugsvsummit.com/gsv-cup. About Primer Primer is an AI personal companion poised to revolutionize the digital learning landscape, with the market expected to reach heights of $370 billion by 2026. Leveraging a patent-pending, generative AI system, Primer offers tailored, engaging experiences that enhance both learning and daily life. Beyond traditional education, Primer learns and grows with each user, continuously evolving to meet their personal needs. It’s this seamless ability to customize learning for everyone, from inquisitive schoolchildren to professionals advancing their careers, that underscores Primer’s dedication to ensuring no one navigates through life without a worldclass advocate. About ASU+GSV Summit Now celebrating its 15th year, the ASU+GSV Summit has become the world's most important and impactful gathering of leaders across "Pre-K to Gray" education and workforce learning. Hosted in San Diego, the annual event attracts over 7,000 in-person and 10,000 virtual registrants. Past GSV keynote speakers and honorees have included Presidents George Bush, Barack Obama and Vicente Fox Quesada, Former Secretaries of Education Arne Duncan and John King, Surgeon General Vivek Murthy, Gina Raimondo, Reed Hastings, John Legend, Condoleezza Rice, Justice Sandra Day O'Connor, Priscilla Chan, Laurene Powell Jobs, and more. ### For Media Relations contact: Mark Naufel,, info@primer.net Contact Details Primer Mark Naufel +1 302-597-6768 info@primer.net Company Website https://primer.net/

February 07, 2024 12:10 AM Eastern Standard Time

Image

Eat To Think: The Power of Nutrient-Dense Foods for Enhanced Cognitive Function!

YourUpdateTV

No one wants to slip into their later years with a failing memory or inability to think clearly and make decisions. Recently Peter Castleman, Author of “Eat to Think: Big Pharma Wants You to Take Pills Forever. We Don't.”, conducted a satellite media tour to share tips and advice on how to use nutritious food to help support your brain health and cognitive function. A video accompanying this announcement is available at: https://youtu.be/-jYERLSPs80 If you’re over 50, you’re most likely a part of the growing number of people who fear a gradual loss of brain function, otherwise known as cognitive decline or dementia. It’s normal to worry. But there is good news. Cognitive decline is mostly the result of lifestyle choices, not genetics. It is simply a story of “too little/too much “- too little of the nutrients your brain needs daily to maintain health and too much of the foods, drugs, and poor lifestyle choices that damage the brain. Nutrient Survival, the pioneering force in Special Ops Grade nutritional innovation, announces the launch of the book “ Eat to Think,” co-authored by Peter M. Castleman and B. Eric Christianson and available now on Amazon. The book explores the beauty of the brain and how it is designed to regenerate forever while empowering readers with Six Pillars of Brilliance to strengthen brain health and longevity. Both Christianson, CEO of Nutrient Survival, and Castleman, Chairman of Nutrient Institute, a non-profit dedicated to improving human nutrition, were spurred to write “Eat to Think” after researching the damage to human health created by common nutritional habits and an over dependence on “Big Pharma” to address health symptoms versus root issues. “In today’s society we have come to accept the inevitable degeneration of our brains and mental function, which does not need to be our fate,” insists Castleman. “Declining mental faculties with age is typically a product of ‘neuroinflammation,’ a process that gradually damages brain cells but can be reversed with proper nutrition. We have the power to regenerate our brain cells within literal reach of our pantries and refrigerators.” Much of the nutritional science and functional ingredients discussed in “Eat to Think'' are incorporated into Nutrient Survival’s newest BrainCare® product launch, the Brain Omega 3 Bar®. An all-natural solution to support brain performance, each Brain Omega 3 Bar® features a patent-pending combination of 1,948mg of Omega 3s, 40 essential nutrients including 27 vitamins and minerals, naturally occurring flavonoids and 8g of protein, all offering better bioavailability of ingredients to nourish both your brain and body. Brain Omega 3 Bar - Fig & Dark Chocolate contains sweet ripe figs, rich dark chocolate, and tart cranberry pieces. Brain Omega 3 Bar - Fig & Roasted Peanut offers ground peanut with sweet ripe figs, semi-sweet chocolate, and creamy peanut morsels. Both flavors are blended with rolled oats, organic rice crisps, milled flax and hemp seeds and feature the following: ● 1,948 mg of Omega 3 (EPA 430 mg + DHA 323 mg + ALA 1,160mg + SDA 35mg) ● 40 essential nutrients ● 27 vitamins and minerals ● 8g of protein including 1.5g of collagen ● Natural flavonoids from semi-sweet chocolate, figs and peanuts ● No artificial colors, flavors or preservatives ● Gluten free The Brain Omega 3 Bar® is available for $2.75 a bar in bags of 15 at nutrientsurvival.com. For more info on the book visit eattothink.com - About Nutrient Survival Nutrient Survival LLC is an end-to-end food technology company offering nutrient dense survival food for emergencies and every day. Nutrient Survival has experienced explosive growth since its introduction in 2020, behind its patented nutrient dense products and compelling brand proposition. Designed to the same nutritional requirements of the US military for its elite Special Ops units, the brand delivers six times more nutrition than any other survival food brand. Nutrient Survival meals designed using the nutritional standards specified in Department of Defense pubs AR 40-25/OPNAVINST 10110.1/MCO 10110.49/AFI 44–141 for Restricted Rations, those rations intended for use on special operations missions. Meals meet or exceed standards for 23 nutrients on a per calorie basis. Neither the US Armed Forces nor the US Federal Government has approved, endorsed or authorized this product. The opinions expressed are solely those of the individual's. About the Authors Peter M. Castleman. Chairman of Nutrient Survival; Chairman of WISEcode; Chairman of Nutrient Institute. A lifetime entrepreneur who for the past decade has been dedicated to improving human nutrition and information about what is in our foods. Castleman graduated from Duke University at the top of his class in Economics, became a Professor at Harvard, then worked on Wall Street. Castleman bought North Face outerwear company when it was going bankrupt and turned it into a 3 billion per year company and then sold it. He did the same with Igloo, Herbalife, and many others. Castleman aims to empower consumers to manage wellness, instead of being controlled by Big Food, Big Ag, and Big Pharma. With good information, Castleman believes humans can make informed decisions with their lifestyle choices. B. Eric Christianson. CEO of Nutrient Survival; Army Veteran; Airborne Ranger qualified; West Point Distinguished Cadet graduate. After a career of leading iconic food brands at Fortune 100 companies, Christianson found his lifelong calling when he was asked by Castleman to build a company called Nutrient Survival. Born at the start of the pandemic, Nutrient Survival is a disruptive end-to-end food company based in Reno-Tahoe, Nevada, that redefines survival food – and all food for that matter – with performance nutrition. With its patented products, Nutrient Survival brings top shelf, delicious, Special Ops grade nutrition. Designed to the same elite nutritional standards of the military for its Special Operations Forces but intended for people like us. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 06, 2024 03:31 PM Eastern Standard Time

Video

1 ... 55 56 57 58 59 ... 301